CN1678630A - 具有修饰的ns3结构域的hcv融合蛋白 - Google Patents

具有修饰的ns3结构域的hcv融合蛋白 Download PDF

Info

Publication number
CN1678630A
CN1678630A CNA038207192A CN03820719A CN1678630A CN 1678630 A CN1678630 A CN 1678630A CN A038207192 A CNA038207192 A CN A038207192A CN 03820719 A CN03820719 A CN 03820719A CN 1678630 A CN1678630 A CN 1678630A
Authority
CN
China
Prior art keywords
polypeptide
ser
asp
ala
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038207192A
Other languages
English (en)
Chinese (zh)
Inventor
M·霍格顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of CN1678630A publication Critical patent/CN1678630A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNA038207192A 2002-07-02 2003-07-02 具有修饰的ns3结构域的hcv融合蛋白 Pending CN1678630A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39369402P 2002-07-02 2002-07-02
US60/393,694 2002-07-02
US39451002P 2002-07-08 2002-07-08
US60/394,510 2002-07-08

Publications (1)

Publication Number Publication Date
CN1678630A true CN1678630A (zh) 2005-10-05

Family

ID=30118384

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038207192A Pending CN1678630A (zh) 2002-07-02 2003-07-02 具有修饰的ns3结构域的hcv融合蛋白

Country Status (8)

Country Link
EP (1) EP1539809A4 (enExample)
JP (2) JP2005532064A (enExample)
CN (1) CN1678630A (enExample)
AU (1) AU2003248818A1 (enExample)
CA (1) CA2491508A1 (enExample)
PL (1) PL374349A1 (enExample)
RU (1) RU2005102484A (enExample)
WO (1) WO2004005473A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749672A (zh) * 2016-11-18 2017-05-31 江西农业大学 一种丙型肝炎病毒融合抗原蛋白及其应用
CN107735499A (zh) * 2015-03-27 2018-02-23 奥索临床诊断有限公司 Hcv ns4a/经修饰的ns3多肽及其用途
CN111153963A (zh) * 2020-01-19 2020-05-15 华南理工大学 抗炎五肽及其提取分离方法和在改善记忆中的应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491808B2 (en) * 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
WO2004039950A2 (en) * 2002-10-25 2004-05-13 Chiron Corporation Activation of hcv-specific cells
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
RU2006144714A (ru) * 2004-05-17 2008-06-27 Чирон Корпорейшн (Us) Усеченный ns5 домен вируса гепатита с и содержащие его слитые белки
ES2377978T3 (es) * 2004-08-27 2012-04-03 Novartis Vaccines And Diagnostics, Inc. Mutantes de proteínas no estructurales de VHC y usos de los mismos
AU2011254055B2 (en) * 2004-10-18 2012-12-20 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP1888751A2 (en) * 2005-05-25 2008-02-20 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
WO2007041861A1 (en) * 2005-10-13 2007-04-19 Virexx Medical Corp. Chimeric antigen containing hepatitis c virus polypeptide and fc fragment for eliciting an immune response
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2061888A2 (en) * 2006-08-25 2009-05-27 Novartis AG Hcv fusion polypeptides
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
US9321847B2 (en) 2010-09-20 2016-04-26 Ramot At Tel Aviv University Ltd. Activatable toxin complexes comprising a cleavable inhibitory peptide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239819T3 (es) * 1993-11-04 2005-10-01 Innogenetics N.V. Epitopos inmunodominantes de celulas t humanas del virus de la hepatitis c.
EP1233982B1 (en) * 1999-11-24 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Novel hcv non-structural polypeptide
WO2001090812A1 (en) * 2000-05-23 2001-11-29 Massachusetts Institute Of Technology Ultraviolet fluoride nonlinear devices

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735499A (zh) * 2015-03-27 2018-02-23 奥索临床诊断有限公司 Hcv ns4a/经修饰的ns3多肽及其用途
CN106749672A (zh) * 2016-11-18 2017-05-31 江西农业大学 一种丙型肝炎病毒融合抗原蛋白及其应用
CN106749672B (zh) * 2016-11-18 2020-06-30 江西农业大学 一种丙型肝炎病毒融合抗原蛋白及其应用
CN111153963A (zh) * 2020-01-19 2020-05-15 华南理工大学 抗炎五肽及其提取分离方法和在改善记忆中的应用
CN111153963B (zh) * 2020-01-19 2021-08-10 华南理工大学 抗炎五肽及其提取分离方法和在改善记忆中的应用

Also Published As

Publication number Publication date
CA2491508A1 (en) 2004-01-15
JP2006265267A (ja) 2006-10-05
WO2004005473A2 (en) 2004-01-15
PL374349A1 (en) 2005-10-17
JP2005532064A (ja) 2005-10-27
WO2004005473A3 (en) 2004-04-01
RU2005102484A (ru) 2006-01-20
AU2003248818A1 (en) 2004-01-23
EP1539809A2 (en) 2005-06-15
EP1539809A4 (en) 2006-03-08

Similar Documents

Publication Publication Date Title
CN1678630A (zh) 具有修饰的ns3结构域的hcv融合蛋白
CN1282656C (zh) 来自gagp17和p24保守区域的HIV肽以及它们在例如疫苗中的应用
US6562346B1 (en) Activation of HCV-specific T cells
CN1833022A (zh) 包含HCV的多蛋白NS3/NS4和多肽NS5b的组合物,包括相应核酸序列的表达载体及它们的治疗应用
CN1636015A (zh) Hcv e1e2疫苗组合物
CN1125877C (zh) 庚型肝炎病毒及其分子克隆
CN1425027A (zh) 新颖的hcv非结构多肽
CN1452634A (zh) Hla结合肽及其用途
CN1741817A (zh) 丙型肝炎病毒密码子优化的非结构ns3/4a融合基因
CN1469755A (zh) 包含病毒唑的疫苗及其使用方法
US7439058B2 (en) HBV/HCV virus-like particle
JP4647870B2 (ja) Ｈｂｖ／ｈｃｖウイルス様粒子
US20050074465A1 (en) HCV fusion proteins with modified NS3 domains
CN1984677A (zh) 截短的丙肝病毒ns5结构域以及含有该截短结构域的融合蛋白
CN101039955A (zh) 与sars冠状病毒刺突蛋白相关的核酸、多肽、表达方法和免疫原性组合物
HK1084147A (en) Hcv fusion proteins with modified ns3 domains
CA2505611A1 (en) Activation of hcv-specific cells
CN1809584A (zh) 含有阳离子微粒和hcv e1e2 dna的组合物及其使用方法
EP1535628B1 (en) Hbv/hcv virus-like particle
HK1059940B (en) Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1084147

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1084147

Country of ref document: HK